Clinical Advances in the Development of New Generation PARP1- Selective Inhibitors
Time: 3:15 pm
day: Day Two
Details:
- Understanding how next-gen PARP1 selective inhibitors maintain efficacy while mitigating toxic side effects
- Uncovering the ways in which these new molecules diversify the application scenarios of PARP inhibitors in clinic
- Outlining which novel DDR targets are showing preclinical & clinical potential for the next wave of cancer-targeting drug approvals
